Pre-earnings brief
Reports
Tue, Aug 11, 2026
Est. EPS
$-0.39
Est. revenue
$0M
Implied move
±5.0%
EPS beat rate
25%
Centessa Pharmaceuticals plc is a biotechnology company focused on developing innovative medicines to address unmet medical needs. Operating in the health care sector, its work is crucial as it aims to bring new therapies to market, particularly in areas where existing treatments are limited or ineffective.
Last quarter
In Q1-2026, Centessa reported an EPS of $-0.52, missing the estimate of $-0.38. The stock reacted with a slight decline of 0.08% the following day.
EPS beat streak
0Q
EPS beat rate
25%
Avg EPS surprise
-51.59%
Avg 1-day reaction
+6.48%
Analysts are expecting Centessa to report an EPS of $-0.39, indicating continued losses as the company invests heavily in research and development.
Bull case
If Centessa can demonstrate progress in its clinical trials or secure new partnerships, it could lead to a positive shift in investor sentiment and stock price.
Bear case
Conversely, if the company fails to provide any updates on its pipeline or reports larger-than-expected losses, it could further erode investor confidence.
Key metrics to watch
EPS
$-0.39Earnings per share (EPS) is a key indicator of the company's profitability and financial health, which investors closely monitor.
Revenue
$0MWhile no revenue is expected this quarter, any updates on future revenue streams or partnerships could significantly impact investor sentiment.
The print will turn on these.
Q1
What updates can management provide on the progress of ongoing clinical trials?
Investors will be keen to understand the status of the company's drug pipeline, as this could significantly influence future revenue potential.
Q2
Will there be any guidance on expected timelines for product launches or partnerships?
Clear timelines can help investors gauge the company's path to profitability and the potential for future revenue.
Why consensus could be wrong
The Street may be underestimating the potential for Centessa's pipeline to deliver breakthrough therapies, which could lead to significant revenue opportunities.
Supporting evidence
The company has a history of surprising investors with positive trial results, despite recent misses.
Options pricing suggests lower volatility than historical averages, indicating potential for unexpected movement.
Key risk
If clinical trial results exceed expectations, it could lead to a substantial reevaluation of the company's growth prospects.
Pre-commit to what would confirm each case.
The market is weighing the potential for future revenue against the backdrop of ongoing losses, making updates on clinical trials and partnerships critical.
Bull confirmed if
Demonstrating significant progress in clinical trials with positive results could confirm the bull case.
Bear confirmed if
Failure to provide any updates on the pipeline or larger-than-expected losses would confirm the bear case.
What the market is pricing for the move.
Implied Move
±5%
Historical Avg
±8.2%
The options market is pricing in a 5% move in either direction, suggesting that investors are anticipating some volatility around the earnings report.
Options are pricing ±5.0% while CNTA has averaged ±8.2% over the last 8 prints — setup is pricing cheap.
30d HV
3.6%
Cross-company pattern from 30 similar setups.
Prior-quarter miss + options pricing cheap setup in Health Care
Fade rate: 13 of 30 (43%)
This setup has occurred 30 times across Health Care in the last 2 years. 13 of 30 faded and 17 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 4.6%, with a raw directional average of +2.0% (modestly positive historical bias).
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Centessa beats expectations and raises guidance, history suggests a potential average one-day move of +0.04%, confirming a positive outlook.
In line / cautious
If results are in line with expectations but management is cautious, the stock may experience a muted reaction, reflecting uncertainty.
Miss
Should the company miss expectations, history suggests an average one-day move of +8.63%, indicating a negative sentiment could prevail.
The lines on the call that would change the story.
—
Est. EPS
$0.20
Est. Rev
$609M
Impl. Move
±12.7%